Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Fundamental Analysis

NASDAQ:HCWB - Nasdaq - US40423R2040 - Common Stock - Currency: USD

4.195  +0.07 (+1.7%)

Fundamental Rating

1

Taking everything into account, HCWB scores 1 out of 10 in our fundamental rating. HCWB was compared to 551 industry peers in the Biotechnology industry. HCWB has a bad profitability rating. Also its financial health evaluation is rather negative. HCWB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HCWB has reported negative net income.
In the past year HCWB has reported a negative cash flow from operations.
In the past 5 years HCWB always reported negative net income.
HCWB had a negative operating cash flow in each of the past 5 years.
HCWB Yearly Net Income VS EBIT VS OCF VS FCFHCWB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -93.10%, HCWB is not doing good in the industry: 73.87% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -93.1%
ROE N/A
ROIC N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HCWB Yearly ROA, ROE, ROICHCWB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

HCWB's Gross Margin of 23.92% is fine compared to the rest of the industry. HCWB outperforms 73.14% of its industry peers.
HCWB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HCWB Yearly Profit, Operating, Gross MarginsHCWB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCWB has more shares outstanding than it did 1 year ago.
HCWB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HCWB is higher compared to a year ago.
HCWB Yearly Shares OutstandingHCWB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
HCWB Yearly Total Debt VS Total AssetsHCWB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

HCWB has an Altman-Z score of -9.32. This is a bad value and indicates that HCWB is not financially healthy and even has some risk of bankruptcy.
HCWB has a worse Altman-Z score (-9.32) than 71.69% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.32
ROIC/WACCN/A
WACC9.63%
HCWB Yearly LT Debt VS Equity VS FCFHCWB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.07 indicates that HCWB may have some problems paying its short term obligations.
HCWB has a Current ratio of 0.07. This is amonst the worse of the industry: HCWB underperforms 97.46% of its industry peers.
HCWB has a Quick Ratio of 0.07. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
HCWB has a worse Quick ratio (0.07) than 97.28% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
HCWB Yearly Current Assets VS Current LiabilitesHCWB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.63% over the past year.
HCWB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.17%.
EPS 1Y (TTM)16.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.5%
Revenue 1Y (TTM)-63.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.55%

3.2 Future

The Earnings Per Share is expected to grow by 23.44% on average over the next years. This is a very strong growth
HCWB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 109.56% yearly.
EPS Next Y79.82%
EPS Next 2Y33.43%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue Next Year-23.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y109.56%

3.3 Evolution

HCWB Yearly Revenue VS EstimatesHCWB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 2028 2029 2030 200M 400M 600M
HCWB Yearly EPS VS EstimatesHCWB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HCWB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HCWB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HCWB Price Earnings VS Forward Price EarningsHCWB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCWB Per share dataHCWB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

A more expensive valuation may be justified as HCWB's earnings are expected to grow with 23.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.43%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

HCWB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HCW BIOLOGICS INC

NASDAQ:HCWB (8/4/2025, 4:30:02 PM)

4.195

+0.07 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/dmh
Earnings (Next)N/A N/A
Inst Owners1.47%
Inst Owner Change-7.9%
Ins Owners29.68%
Ins Owner Change18.01%
Market Cap8.26M
Analysts82.86
Price Target35.7 (751.01%)
Short Float %3.76%
Short Ratio0.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-70.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)79.09%
EPS NY rev (3m)79.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-25.14
EYN/A
EPS(NY)-5.11
Fwd EYN/A
FCF(TTM)-7.25
FCFYN/A
OCF(TTM)-7.18
OCFYN/A
SpS0.73
BVpS-4.35
TBVpS-4.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.92%
FCFM N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.65%
Cap/Sales 9.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -9.32
F-Score1
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)665.42%
Cap/Depr(5y)407.44%
Cap/Sales(3y)127.14%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.5%
EPS Next Y79.82%
EPS Next 2Y33.43%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-63.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.55%
Revenue Next Year-23.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y109.56%
EBIT growth 1Y17.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.68%
OCF growth 3YN/A
OCF growth 5YN/A